Cargando…
Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model
Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low. Therefore, efforts are being undertaken to sensitize tumors for immune checkpoint blockade, which includes combining immune checkpoint blocking agent...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513675/ https://www.ncbi.nlm.nih.gov/pubmed/33014872 http://dx.doi.org/10.3389/fonc.2020.01771 |
_version_ | 1783586431431606272 |
---|---|
author | Sirait-Fischer, Evelyn Olesch, Catherine Fink, Annika F. Berkefeld, Matthias Huard, Arnaud Schmid, Tobias Takeda, Kazuhiko Brüne, Bernhard Weigert, Andreas |
author_facet | Sirait-Fischer, Evelyn Olesch, Catherine Fink, Annika F. Berkefeld, Matthias Huard, Arnaud Schmid, Tobias Takeda, Kazuhiko Brüne, Bernhard Weigert, Andreas |
author_sort | Sirait-Fischer, Evelyn |
collection | PubMed |
description | Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low. Therefore, efforts are being undertaken to sensitize tumors for immune checkpoint blockade, which includes combining immune checkpoint blocking agents such as anti-PD-1 antibodies with standard of care treatments. Here we report that a combination of chemotherapy (doxorubicin) and immune checkpoint blockade (anti-PD-1 antibodies) induces superior tumor control compared to chemotherapy and immune checkpoint blockade alone in the murine autochthonous polyoma middle T oncogene-driven (PyMT) mammary tumor model. Using whole transcriptome analysis, we identified a set of genes that were upregulated specifically upon chemoimmunotherapy. This gene signature and, more specifically, a condensed four-gene signature predicted favorable survival of human mammary carcinoma patients in the METABRIC cohort. Moreover, PyMT tumors treated with chemoimmunotherapy contained higher levels of cytotoxic lymphocytes, particularly natural killer cells (NK cells). Gene set enrichment analysis and bead-based ELISA measurements revealed increased IL-27 production and signaling in PyMT tumors upon chemoimmunotherapy. Moreover, IL-27 signaling improved NK cell cytotoxicity against PyMT cells in vitro. Taken together, our data support recent clinical observations indicating a benefit of chemoimmunotherapy compared to monotherapy in breast cancer and suggest potential underlying mechanisms. |
format | Online Article Text |
id | pubmed-7513675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75136752020-10-02 Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model Sirait-Fischer, Evelyn Olesch, Catherine Fink, Annika F. Berkefeld, Matthias Huard, Arnaud Schmid, Tobias Takeda, Kazuhiko Brüne, Bernhard Weigert, Andreas Front Oncol Oncology Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low. Therefore, efforts are being undertaken to sensitize tumors for immune checkpoint blockade, which includes combining immune checkpoint blocking agents such as anti-PD-1 antibodies with standard of care treatments. Here we report that a combination of chemotherapy (doxorubicin) and immune checkpoint blockade (anti-PD-1 antibodies) induces superior tumor control compared to chemotherapy and immune checkpoint blockade alone in the murine autochthonous polyoma middle T oncogene-driven (PyMT) mammary tumor model. Using whole transcriptome analysis, we identified a set of genes that were upregulated specifically upon chemoimmunotherapy. This gene signature and, more specifically, a condensed four-gene signature predicted favorable survival of human mammary carcinoma patients in the METABRIC cohort. Moreover, PyMT tumors treated with chemoimmunotherapy contained higher levels of cytotoxic lymphocytes, particularly natural killer cells (NK cells). Gene set enrichment analysis and bead-based ELISA measurements revealed increased IL-27 production and signaling in PyMT tumors upon chemoimmunotherapy. Moreover, IL-27 signaling improved NK cell cytotoxicity against PyMT cells in vitro. Taken together, our data support recent clinical observations indicating a benefit of chemoimmunotherapy compared to monotherapy in breast cancer and suggest potential underlying mechanisms. Frontiers Media S.A. 2020-09-10 /pmc/articles/PMC7513675/ /pubmed/33014872 http://dx.doi.org/10.3389/fonc.2020.01771 Text en Copyright © 2020 Sirait-Fischer, Olesch, Fink, Berkefeld, Huard, Schmid, Takeda, Brüne and Weigert. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Sirait-Fischer, Evelyn Olesch, Catherine Fink, Annika F. Berkefeld, Matthias Huard, Arnaud Schmid, Tobias Takeda, Kazuhiko Brüne, Bernhard Weigert, Andreas Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model |
title | Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model |
title_full | Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model |
title_fullStr | Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model |
title_full_unstemmed | Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model |
title_short | Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model |
title_sort | immune checkpoint blockade improves chemotherapy in the pymt mammary carcinoma mouse model |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513675/ https://www.ncbi.nlm.nih.gov/pubmed/33014872 http://dx.doi.org/10.3389/fonc.2020.01771 |
work_keys_str_mv | AT siraitfischerevelyn immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel AT oleschcatherine immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel AT finkannikaf immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel AT berkefeldmatthias immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel AT huardarnaud immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel AT schmidtobias immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel AT takedakazuhiko immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel AT brunebernhard immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel AT weigertandreas immunecheckpointblockadeimproveschemotherapyinthepymtmammarycarcinomamousemodel |